 Liron Caplan
Concepts (357)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spondylitis, Ankylosing | 12 | 2024 | 46 | 5.800 |
Why?
| | Arthritis, Rheumatoid | 52 | 2025 | 1167 | 4.980 |
Why?
| | Rheumatology | 15 | 2023 | 118 | 4.290 |
Why?
| | Spondylarthritis | 10 | 2024 | 50 | 4.040 |
Why?
| | Antirheumatic Agents | 27 | 2019 | 293 | 3.620 |
Why?
| | Osteoporosis | 10 | 2023 | 243 | 1.930 |
Why?
| | Glucocorticoids | 11 | 2025 | 594 | 1.750 |
Why?
| | Severity of Illness Index | 26 | 2023 | 2828 | 1.550 |
Why?
| | Health Literacy | 5 | 2019 | 168 | 1.530 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 5 | 2023 | 350 | 1.480 |
Why?
| | Gastrointestinal Diseases | 3 | 2018 | 209 | 1.440 |
Why?
| | Methotrexate | 11 | 2018 | 260 | 1.140 |
Why?
| | Arthritis | 2 | 2019 | 95 | 1.100 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 3 | 2015 | 250 | 1.070 |
Why?
| | Registries | 21 | 2025 | 2035 | 1.030 |
Why?
| | Decision Support Systems, Management | 2 | 2015 | 6 | 0.920 |
Why?
| | Methylenetetrahydrofolate Reductase (NADPH2) | 2 | 2014 | 36 | 0.830 |
Why?
| | Sacroiliitis | 1 | 2022 | 6 | 0.800 |
Why?
| | Fractures, Bone | 3 | 2023 | 380 | 0.750 |
Why?
| | Veterans | 14 | 2025 | 1476 | 0.740 |
Why?
| | Bone Density Conservation Agents | 4 | 2014 | 80 | 0.720 |
Why?
| | Cardiovascular Diseases | 9 | 2023 | 2111 | 0.720 |
Why?
| | Humans | 101 | 2025 | 137585 | 0.680 |
Why?
| | Health Knowledge, Attitudes, Practice | 4 | 2015 | 1329 | 0.680 |
Why?
| | Outpatient Clinics, Hospital | 2 | 2011 | 82 | 0.670 |
Why?
| | Arthritis, Psoriatic | 2 | 2023 | 21 | 0.670 |
Why?
| | Body Mass Index | 10 | 2018 | 2389 | 0.640 |
Why?
| | Transportation | 1 | 2019 | 53 | 0.630 |
Why?
| | Drug Packaging | 1 | 2019 | 45 | 0.620 |
Why?
| | Rheumatic Diseases | 2 | 2018 | 81 | 0.610 |
Why?
| | Inflammatory Bowel Diseases | 3 | 2018 | 351 | 0.600 |
Why?
| | Gastrointestinal Tract | 2 | 2018 | 195 | 0.590 |
Why?
| | Conflict of Interest | 1 | 2020 | 130 | 0.590 |
Why?
| | Visual Analog Scale | 2 | 2019 | 33 | 0.580 |
Why?
| | Prednisone | 6 | 2025 | 240 | 0.570 |
Why?
| | United States | 34 | 2025 | 14841 | 0.570 |
Why?
| | Antibodies, Antineutrophil Cytoplasmic | 1 | 2018 | 36 | 0.560 |
Why?
| | Aged | 45 | 2025 | 23961 | 0.560 |
Why?
| | Pharmaceutical Preparations | 1 | 2019 | 179 | 0.550 |
Why?
| | Joints | 3 | 2013 | 105 | 0.550 |
Why?
| | Vasculitis | 1 | 2018 | 66 | 0.540 |
Why?
| | Disability Evaluation | 2 | 2018 | 290 | 0.540 |
Why?
| | Middle Aged | 49 | 2025 | 33479 | 0.530 |
Why?
| | Medication Therapy Management | 1 | 2018 | 76 | 0.530 |
Why?
| | Diphosphonates | 3 | 2014 | 66 | 0.520 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2018 | 137 | 0.510 |
Why?
| | Tumor Necrosis Factor-alpha | 8 | 2022 | 1242 | 0.500 |
Why?
| | Cross-Sectional Studies | 16 | 2019 | 5472 | 0.480 |
Why?
| | Male | 58 | 2025 | 67762 | 0.470 |
Why?
| | Health Care Costs | 1 | 2019 | 398 | 0.470 |
Why?
| | Patient Satisfaction | 2 | 2019 | 660 | 0.460 |
Why?
| | Patient Education as Topic | 4 | 2015 | 766 | 0.460 |
Why?
| | Liver Diseases | 1 | 2018 | 315 | 0.450 |
Why?
| | Practice Patterns, Physicians' | 3 | 2015 | 1313 | 0.450 |
Why?
| | Surveys and Questionnaires | 7 | 2016 | 5778 | 0.440 |
Why?
| | gamma-Glutamyl Hydrolase | 1 | 2014 | 3 | 0.440 |
Why?
| | Attitude of Health Personnel | 2 | 2013 | 1171 | 0.440 |
Why?
| | Peptide Synthases | 1 | 2014 | 5 | 0.440 |
Why?
| | Weight Loss | 5 | 2018 | 787 | 0.440 |
Why?
| | Veterans Health | 5 | 2017 | 186 | 0.430 |
Why?
| | Diabetes Mellitus, Type 2 | 4 | 2022 | 2531 | 0.430 |
Why?
| | Proteins | 1 | 2019 | 1009 | 0.410 |
Why?
| | Spondylarthropathies | 3 | 2019 | 6 | 0.410 |
Why?
| | Health Status | 3 | 2018 | 792 | 0.410 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 916 | 0.410 |
Why?
| | Risk Factors | 24 | 2023 | 10388 | 0.400 |
Why?
| | Female | 51 | 2025 | 73304 | 0.400 |
Why?
| | Societies, Medical | 5 | 2019 | 820 | 0.400 |
Why?
| | Biomedical Research | 1 | 2019 | 692 | 0.400 |
Why?
| | Lipids | 2 | 2014 | 672 | 0.400 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2015 | 177 | 0.390 |
Why?
| | Symptom Assessment | 1 | 2013 | 128 | 0.390 |
Why?
| | Folic Acid | 1 | 2014 | 186 | 0.390 |
Why?
| | Activities of Daily Living | 1 | 2016 | 413 | 0.390 |
Why?
| | Consumer Behavior | 1 | 2013 | 71 | 0.390 |
Why?
| | Physical Therapy Modalities | 1 | 2015 | 308 | 0.380 |
Why?
| | Pharmacists | 1 | 2015 | 265 | 0.380 |
Why?
| | Patient Reported Outcome Measures | 1 | 2016 | 402 | 0.380 |
Why?
| | Hospitals, Public | 1 | 2011 | 29 | 0.360 |
Why?
| | Obesity | 5 | 2018 | 2992 | 0.360 |
Why?
| | Health Personnel | 3 | 2014 | 710 | 0.360 |
Why?
| | Electronic Health Records | 3 | 2015 | 1069 | 0.360 |
Why?
| | Pain | 2 | 2022 | 756 | 0.360 |
Why?
| | Anti-Inflammatory Agents | 4 | 2018 | 496 | 0.320 |
Why?
| | Telemedicine | 1 | 2019 | 862 | 0.320 |
Why?
| | Autoantibodies | 5 | 2019 | 1496 | 0.320 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 140 | 0.310 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2022 | 1477 | 0.310 |
Why?
| | Cerebrovascular Disorders | 3 | 1997 | 96 | 0.310 |
Why?
| | Physician-Patient Relations | 2 | 2011 | 548 | 0.300 |
Why?
| | Workflow | 1 | 2010 | 165 | 0.300 |
Why?
| | Musculoskeletal Diseases | 1 | 2010 | 78 | 0.300 |
Why?
| | Adalimumab | 4 | 2020 | 48 | 0.300 |
Why?
| | Linear Models | 5 | 2019 | 849 | 0.300 |
Why?
| | Publications | 1 | 2008 | 47 | 0.280 |
Why?
| | Practice Guidelines as Topic | 5 | 2018 | 1587 | 0.280 |
Why?
| | Ethics, Medical | 1 | 2008 | 84 | 0.280 |
Why?
| | CARD Signaling Adaptor Proteins | 2 | 2024 | 21 | 0.280 |
Why?
| | Patient Compliance | 1 | 2012 | 581 | 0.280 |
Why?
| | United States Department of Veterans Affairs | 8 | 2016 | 678 | 0.270 |
Why?
| | Etanercept | 3 | 2016 | 57 | 0.270 |
Why?
| | Radiography | 3 | 2019 | 822 | 0.260 |
Why?
| | Aged, 80 and over | 11 | 2019 | 7635 | 0.260 |
Why?
| | Infliximab | 3 | 2016 | 111 | 0.250 |
Why?
| | Diabetes Mellitus | 1 | 2015 | 1040 | 0.250 |
Why?
| | Time Factors | 12 | 2018 | 6828 | 0.250 |
Why?
| | Adult | 20 | 2023 | 37929 | 0.250 |
Why?
| | Ambulatory Care | 1 | 2010 | 546 | 0.250 |
Why?
| | Drug Utilization | 3 | 2018 | 169 | 0.240 |
Why?
| | Treatment Outcome | 13 | 2019 | 10811 | 0.240 |
Why?
| | Professional Practice | 1 | 2005 | 64 | 0.230 |
Why?
| | Peptides, Cyclic | 4 | 2016 | 259 | 0.220 |
Why?
| | Longitudinal Studies | 9 | 2019 | 2844 | 0.220 |
Why?
| | Quality of Life | 1 | 2016 | 2892 | 0.210 |
Why?
| | HLA-B27 Antigen | 2 | 2024 | 16 | 0.210 |
Why?
| | Reproducibility of Results | 5 | 2016 | 3284 | 0.210 |
Why?
| | Rheumatoid Factor | 3 | 2016 | 175 | 0.210 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2019 | 2189 | 0.210 |
Why?
| | Cohort Studies | 11 | 2015 | 5742 | 0.210 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2014 | 2057 | 0.200 |
Why?
| | Magnetic Resonance Imaging | 4 | 2025 | 3566 | 0.200 |
Why?
| | Predictive Value of Tests | 5 | 2018 | 2031 | 0.200 |
Why?
| | Adrenal Cortex Hormones | 1 | 2007 | 565 | 0.200 |
Why?
| | Evidence-Based Medicine | 2 | 2018 | 740 | 0.200 |
Why?
| | Bone Density | 4 | 2023 | 489 | 0.200 |
Why?
| | Myocardial Infarction | 3 | 2018 | 1046 | 0.190 |
Why?
| | Retrospective Studies | 11 | 2022 | 15657 | 0.190 |
Why?
| | Inflammation | 4 | 2018 | 2837 | 0.190 |
Why?
| | Biomarkers | 5 | 2022 | 4149 | 0.180 |
Why?
| | Prognosis | 6 | 2016 | 4030 | 0.170 |
Why?
| | Self Report | 1 | 2025 | 827 | 0.170 |
Why?
| | Multivariate Analysis | 8 | 2018 | 1509 | 0.170 |
Why?
| | Proportional Hazards Models | 6 | 2016 | 1266 | 0.170 |
Why?
| | Lymphocytes | 1 | 2022 | 397 | 0.170 |
Why?
| | Neutrophils | 2 | 2024 | 1238 | 0.170 |
Why?
| | C-Reactive Protein | 3 | 2017 | 410 | 0.170 |
Why?
| | Risk Assessment | 7 | 2018 | 3457 | 0.160 |
Why?
| | Genetic Predisposition to Disease | 5 | 2024 | 2426 | 0.160 |
Why?
| | Granuloma, Foreign-Body | 1 | 2020 | 10 | 0.160 |
Why?
| | Tattooing | 1 | 2020 | 14 | 0.160 |
Why?
| | Regression Analysis | 3 | 2011 | 1024 | 0.160 |
Why?
| | Malondialdehyde | 1 | 2019 | 29 | 0.160 |
Why?
| | Comorbidity | 6 | 2018 | 1622 | 0.160 |
Why?
| | Genotype | 3 | 2014 | 1916 | 0.160 |
Why?
| | Acetaldehyde | 1 | 2019 | 17 | 0.160 |
Why?
| | Macular Edema | 1 | 2020 | 43 | 0.160 |
Why?
| | Drug Compounding | 1 | 2019 | 101 | 0.160 |
Why?
| | Drug Stability | 1 | 2019 | 167 | 0.160 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2019 | 23 | 0.150 |
Why?
| | Blood Platelets | 1 | 2022 | 408 | 0.150 |
Why?
| | Protein Stability | 1 | 2019 | 176 | 0.150 |
Why?
| | Deprescriptions | 1 | 2019 | 35 | 0.150 |
Why?
| | Uveitis | 1 | 2020 | 136 | 0.150 |
Why?
| | Hydroxychloroquine | 2 | 2018 | 58 | 0.150 |
Why?
| | Intraepithelial Lymphocytes | 1 | 2018 | 15 | 0.150 |
Why?
| | Blood Glucose | 4 | 2022 | 2186 | 0.150 |
Why?
| | Metformin | 1 | 2022 | 331 | 0.150 |
Why?
| | Vertebrobasilar Insufficiency | 1 | 1998 | 8 | 0.140 |
Why?
| | Pyrroles | 1 | 2019 | 213 | 0.140 |
Why?
| | Clinical Trials as Topic | 2 | 2022 | 1050 | 0.140 |
Why?
| | Cerebral Infarction | 1 | 1998 | 44 | 0.140 |
Why?
| | Mesencephalon | 1 | 1998 | 66 | 0.140 |
Why?
| | Piperidines | 1 | 2019 | 206 | 0.140 |
Why?
| | Stress, Mechanical | 1 | 2019 | 485 | 0.140 |
Why?
| | Obesity, Abdominal | 1 | 2017 | 48 | 0.140 |
Why?
| | Inflammation Mediators | 2 | 2017 | 513 | 0.130 |
Why?
| | Remission Induction | 3 | 2012 | 288 | 0.130 |
Why?
| | Absorptiometry, Photon | 3 | 2017 | 259 | 0.130 |
Why?
| | Thrombolytic Therapy | 1 | 1997 | 142 | 0.130 |
Why?
| | Temperature | 1 | 2019 | 679 | 0.130 |
Why?
| | Drug Administration Schedule | 2 | 2010 | 786 | 0.130 |
Why?
| | Biological Products | 1 | 2019 | 216 | 0.120 |
Why?
| | Sodium Chloride | 1 | 2016 | 142 | 0.120 |
Why?
| | Pyrimidines | 1 | 2019 | 470 | 0.120 |
Why?
| | Tissue Plasminogen Activator | 1 | 1997 | 224 | 0.120 |
Why?
| | Research Design | 1 | 2022 | 1139 | 0.120 |
Why?
| | Administration, Oral | 2 | 2025 | 816 | 0.120 |
Why?
| | Patient Selection | 3 | 2022 | 696 | 0.110 |
Why?
| | Genes, rel | 1 | 2014 | 4 | 0.110 |
Why?
| | Lipoproteins, HDL | 1 | 2014 | 77 | 0.110 |
Why?
| | DNA Methylation | 1 | 2019 | 643 | 0.110 |
Why?
| | Lipoproteins, LDL | 1 | 2014 | 116 | 0.110 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2019 | 804 | 0.110 |
Why?
| | Hand | 1 | 2015 | 156 | 0.110 |
Why?
| | Disease Management | 1 | 2018 | 628 | 0.100 |
Why?
| | Vascular Calcification | 1 | 2015 | 108 | 0.100 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 1483 | 0.100 |
Why?
| | Spinal Fractures | 1 | 2014 | 73 | 0.100 |
Why?
| | Incidence | 7 | 2018 | 2804 | 0.100 |
Why?
| | Femoral Fractures | 1 | 2014 | 76 | 0.100 |
Why?
| | Algorithms | 2 | 2025 | 1704 | 0.100 |
Why?
| | Lung Diseases, Interstitial | 1 | 2019 | 638 | 0.100 |
Why?
| | Adiposity | 1 | 2017 | 518 | 0.100 |
Why?
| | Dyslipidemias | 1 | 2014 | 176 | 0.100 |
Why?
| | Immunosuppressive Agents | 3 | 2009 | 890 | 0.100 |
Why?
| | Health Services Research | 1 | 2015 | 404 | 0.100 |
Why?
| | North America | 1 | 2013 | 313 | 0.100 |
Why?
| | Immunoglobulin G | 1 | 2016 | 893 | 0.090 |
Why?
| | Chronic Disease | 2 | 2018 | 1793 | 0.090 |
Why?
| | Insurance, Pharmaceutical Services | 1 | 2011 | 22 | 0.090 |
Why?
| | Lung Diseases | 1 | 2018 | 767 | 0.090 |
Why?
| | Autoimmunity | 1 | 2018 | 908 | 0.090 |
Why?
| | Triglycerides | 1 | 2014 | 524 | 0.090 |
Why?
| | Coronary Artery Disease | 1 | 2018 | 698 | 0.090 |
Why?
| | Polymorphism, Genetic | 2 | 2011 | 660 | 0.090 |
Why?
| | Antibodies, Monoclonal | 2 | 2016 | 1430 | 0.090 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2011 | 85 | 0.090 |
Why?
| | Nanoparticles | 1 | 2016 | 481 | 0.090 |
Why?
| | Memory Disorders | 1 | 2012 | 164 | 0.090 |
Why?
| | Glutathione Transferase | 1 | 2010 | 106 | 0.080 |
Why?
| | Gastrointestinal Microbiome | 1 | 2018 | 697 | 0.080 |
Why?
| | Workload | 1 | 2012 | 167 | 0.080 |
Why?
| | Carcinoma, Basal Cell | 1 | 2011 | 75 | 0.080 |
Why?
| | Young Adult | 3 | 2019 | 13209 | 0.080 |
Why?
| | Health Care Surveys | 1 | 2012 | 565 | 0.080 |
Why?
| | HLA-DR Antigens | 1 | 2010 | 228 | 0.080 |
Why?
| | Sex Factors | 4 | 2017 | 2071 | 0.080 |
Why?
| | Follow-Up Studies | 4 | 2015 | 5131 | 0.080 |
Why?
| | Health Surveys | 2 | 2012 | 514 | 0.080 |
Why?
| | Hip Fractures | 1 | 2010 | 86 | 0.080 |
Why?
| | Hypertension | 1 | 2018 | 1295 | 0.080 |
Why?
| | Pilot Projects | 1 | 2014 | 1710 | 0.070 |
Why?
| | Disease Progression | 4 | 2019 | 2757 | 0.070 |
Why?
| | Immunocompromised Host | 2 | 2011 | 202 | 0.070 |
Why?
| | Hospitalization | 2 | 2011 | 2199 | 0.070 |
Why?
| | Vitamin D Deficiency | 1 | 2010 | 186 | 0.070 |
Why?
| | Databases, Bibliographic | 1 | 2008 | 32 | 0.070 |
Why?
| | Epitopes | 1 | 2010 | 479 | 0.070 |
Why?
| | Beneficence | 1 | 2008 | 17 | 0.070 |
Why?
| | Interviews as Topic | 1 | 2012 | 786 | 0.070 |
Why?
| | Cytokines | 1 | 2016 | 2085 | 0.070 |
Why?
| | Self Care | 1 | 2011 | 380 | 0.070 |
Why?
| | Drug Prescriptions | 1 | 2010 | 245 | 0.070 |
Why?
| | Awards and Prizes | 1 | 1989 | 67 | 0.070 |
Why?
| | Prospective Studies | 4 | 2013 | 7604 | 0.070 |
Why?
| | Sensitivity and Specificity | 1 | 2013 | 1946 | 0.070 |
Why?
| | Social Justice | 1 | 2008 | 73 | 0.070 |
Why?
| | Neoplasms | 3 | 2017 | 2671 | 0.070 |
Why?
| | Research Personnel | 1 | 1989 | 173 | 0.070 |
Why?
| | Urban Population | 1 | 2010 | 479 | 0.070 |
Why?
| | Self Administration | 1 | 2007 | 123 | 0.060 |
Why?
| | Infusions, Intravenous | 2 | 2016 | 413 | 0.060 |
Why?
| | Military Personnel | 1 | 2013 | 544 | 0.060 |
Why?
| | Depressive Disorder | 1 | 2009 | 379 | 0.060 |
Why?
| | Quality of Health Care | 1 | 2011 | 642 | 0.060 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2011 | 683 | 0.060 |
Why?
| | Herpes Zoster | 1 | 2009 | 316 | 0.060 |
Why?
| | Age Factors | 4 | 2015 | 3295 | 0.060 |
Why?
| | Respiratory Tract Diseases | 2 | 2017 | 184 | 0.060 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2013 | 847 | 0.060 |
Why?
| | Cause of Death | 2 | 2017 | 434 | 0.060 |
Why?
| | Qualitative Research | 1 | 2012 | 1386 | 0.060 |
Why?
| | Spine | 1 | 2025 | 173 | 0.050 |
Why?
| | Skin Neoplasms | 1 | 2011 | 855 | 0.050 |
Why?
| | Databases, Factual | 3 | 2014 | 1357 | 0.050 |
Why?
| | Immunity, Innate | 2 | 2024 | 828 | 0.050 |
Why?
| | Coculture Techniques | 1 | 2024 | 239 | 0.050 |
Why?
| | Interleukin-17 | 1 | 2024 | 119 | 0.050 |
Why?
| | Survival Analysis | 2 | 2018 | 1325 | 0.050 |
Why?
| | Th17 Cells | 1 | 2024 | 108 | 0.050 |
Why?
| | Autoantigens | 2 | 2019 | 430 | 0.050 |
Why?
| | Antibody Formation | 2 | 2019 | 298 | 0.050 |
Why?
| | Isoxazoles | 2 | 2016 | 54 | 0.050 |
Why?
| | Adolescent | 3 | 2019 | 21513 | 0.050 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2004 | 455 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2019 | 3556 | 0.040 |
Why?
| | Carrier Proteins | 1 | 2004 | 771 | 0.040 |
Why?
| | Pneumonia | 1 | 2006 | 639 | 0.040 |
Why?
| | Prevalence | 1 | 2007 | 2734 | 0.040 |
Why?
| | Foreign-Body Reaction | 1 | 2020 | 31 | 0.040 |
Why?
| | Phospholipase D | 1 | 2019 | 9 | 0.040 |
Why?
| | Steroids | 1 | 2020 | 167 | 0.040 |
Why?
| | Sulfasalazine | 1 | 2018 | 23 | 0.040 |
Why?
| | Intracranial Embolism and Thrombosis | 1 | 1998 | 6 | 0.040 |
Why?
| | New England | 1 | 1998 | 32 | 0.040 |
Why?
| | Coronary Thrombosis | 1 | 1998 | 25 | 0.040 |
Why?
| | Blood Sedimentation | 1 | 2017 | 39 | 0.040 |
Why?
| | Microtubule-Associated Proteins | 1 | 2019 | 196 | 0.040 |
Why?
| | Vulnerable Populations | 1 | 2019 | 163 | 0.040 |
Why?
| | Infusions, Intra-Arterial | 1 | 1997 | 59 | 0.040 |
Why?
| | Child | 3 | 2023 | 21935 | 0.030 |
Why?
| | Molecular Chaperones | 1 | 2019 | 195 | 0.030 |
Why?
| | Visual Acuity | 1 | 2020 | 356 | 0.030 |
Why?
| | Rheumatic Nodule | 1 | 2016 | 3 | 0.030 |
Why?
| | Osteoarthritis | 1 | 2019 | 185 | 0.030 |
Why?
| | Mitochondrial Proteins | 1 | 2019 | 257 | 0.030 |
Why?
| | Machine Learning | 1 | 2022 | 493 | 0.030 |
Why?
| | RNA, Long Noncoding | 1 | 2019 | 181 | 0.030 |
Why?
| | Adsorption | 1 | 2016 | 149 | 0.030 |
Why?
| | Drug Substitution | 1 | 2016 | 54 | 0.030 |
Why?
| | Thinness | 1 | 2016 | 91 | 0.030 |
Why?
| | Nutrition Surveys | 1 | 2017 | 266 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2016 | 155 | 0.030 |
Why?
| | Biopsy | 1 | 2020 | 1129 | 0.030 |
Why?
| | Protein Aggregates | 1 | 2016 | 72 | 0.030 |
Why?
| | Cerebrovascular Circulation | 1 | 1998 | 243 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2004 | 1996 | 0.030 |
Why?
| | Observational Studies as Topic | 1 | 2016 | 117 | 0.030 |
Why?
| | Chemokines | 1 | 2016 | 228 | 0.030 |
Why?
| | Consensus | 1 | 2018 | 683 | 0.030 |
Why?
| | Mortality | 1 | 2018 | 362 | 0.030 |
Why?
| | Particle Size | 1 | 2016 | 394 | 0.030 |
Why?
| | Lymphoma | 1 | 2016 | 208 | 0.030 |
Why?
| | Apolipoproteins E | 1 | 2015 | 83 | 0.030 |
Why?
| | Cardiac Catheterization | 1 | 2018 | 530 | 0.030 |
Why?
| | Interleukin-4 | 1 | 2015 | 216 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2019 | 660 | 0.030 |
Why?
| | Leukemia | 1 | 2016 | 240 | 0.030 |
Why?
| | Antigen-Antibody Complex | 1 | 2014 | 90 | 0.030 |
Why?
| | Hospitals, Veterans | 1 | 2015 | 252 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2014 | 208 | 0.030 |
Why?
| | Causality | 1 | 2014 | 126 | 0.030 |
Why?
| | Life Style | 1 | 2016 | 490 | 0.030 |
Why?
| | Hypoglycemic Agents | 1 | 2022 | 1291 | 0.030 |
Why?
| | Mutation | 1 | 2024 | 3958 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2019 | 1431 | 0.020 |
Why?
| | Body Weight | 1 | 2016 | 985 | 0.020 |
Why?
| | Blood Pressure | 1 | 2018 | 1786 | 0.020 |
Why?
| | Data Mining | 1 | 2011 | 116 | 0.020 |
Why?
| | Survival Rate | 1 | 2015 | 1972 | 0.020 |
Why?
| | HLA-DRB1 Chains | 1 | 2010 | 112 | 0.020 |
Why?
| | Propensity Score | 1 | 2011 | 294 | 0.020 |
Why?
| | Mice | 2 | 2024 | 17787 | 0.020 |
Why?
| | Logistic Models | 1 | 2015 | 2074 | 0.020 |
Why?
| | Prostatic Neoplasms | 1 | 2016 | 1043 | 0.020 |
Why?
| | Medication Adherence | 1 | 2012 | 467 | 0.020 |
Why?
| | Smoking | 1 | 2016 | 1627 | 0.020 |
Why?
| | Pancreatic Neoplasms | 1 | 2016 | 938 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 852 | 0.020 |
Why?
| | Risk | 1 | 2011 | 912 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2010 | 1062 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 1997 | 2691 | 0.020 |
Why?
| | Congresses as Topic | 1 | 1989 | 233 | 0.020 |
Why?
| | American Heart Association | 1 | 1989 | 306 | 0.020 |
Why?
| | Lung | 1 | 2019 | 4060 | 0.020 |
Why?
| | Periodicals as Topic | 1 | 1989 | 211 | 0.020 |
Why?
| | Population Surveillance | 1 | 2009 | 482 | 0.020 |
Why?
| | Signaling Lymphocytic Activation Molecule Associated Protein | 1 | 2004 | 1 | 0.010 |
Why?
| | Signaling Lymphocytic Activation Molecule Family Member 1 | 1 | 2004 | 2 | 0.010 |
Why?
| | Lupus Vulgaris | 1 | 2004 | 5 | 0.010 |
Why?
| | Animals | 2 | 2024 | 36940 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 2009 | 1289 | 0.010 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 1 | 2004 | 68 | 0.010 |
Why?
| | Immunoglobulins | 1 | 2004 | 171 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2016 | 2526 | 0.010 |
Why?
| | Forecasting | 1 | 2004 | 389 | 0.010 |
Why?
| | Glycoproteins | 1 | 2004 | 342 | 0.010 |
Why?
| | Receptors, Cell Surface | 1 | 2004 | 385 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 2004 | 1066 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2004 | 1272 | 0.010 |
Why?
| | Antigens, CD | 1 | 2004 | 521 | 0.010 |
Why?
| | Cell Membrane | 1 | 2004 | 738 | 0.010 |
Why?
| | Autoimmune Diseases | 1 | 2004 | 460 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2004 | 3015 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2004 | 4295 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2004 | 5757 | 0.010 |
Why?
| | Signal Transduction | 1 | 2004 | 5079 | 0.010 |
Why?
|
|
Caplan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|